The stain appears as cytoplasmic, membrane-associated or sometimes as perinuclear dots (34). Although KIT positivity appears to have significant therapeutic implications, the intensity, extent and patters of KIT staining neither correlates with the type of

KIT mutation nor have therapeutic significance (34). It is important to note that negative KIT does not exclude the patient Inhibitors,research,lifescience,medical from being treated with TKI (imatinib or sunitinib) since some wild-type GISTs for both KIT and PDGFRA genes respond to treatment with TKI (42). In addition, CD34 is another common marker for GISTs but it is not as sensitive or specific. It is positive in about 80% of gastric GISTs, 50% of small intestine GISTs, and in 95% of esophageal and colorectal GISTs (48,108) (Figure 5). Other markers which can be expressed by GISTs include h-caldesmon, SMA, S100, desmin, Vimentin, and cytokeratins 8 and 18 (100). Recently other CD markers for GISTs are reported including CD10 (109), CD133, Inhibitors,research,lifescience,medical and CD44 (110). Figure 5 Immunohistochemical features of GIST. A. Spindle cell GIST with strong and diffuse cytoplasmic staining of CD117 (c-kit) (×400); B. Spindel cell GIST Inhibitors,research,lifescience,medical with strong and diffuse http://www.selleckchem.com/products/epz-5676.html membrane staining of CD34 (×400); C. Epithelioid

cell GIST with … A small minority of GIST (<5%) are negative for KIT, or minimally, if any, positive for KIT by immunohistochemistry. These tumors appear to be either KIT wild-type or with mutant PDGFRA, have a predilection to stomach or omentum/peritoneum, and be usually epithelioid or mixed subtype

(91,111). For the special interest in this subgroup of KIT-negative GISTs, several new antibodies for Inhibitors,research,lifescience,medical the diagnosis of GIST have been discovered based on the molecular studies. DOG1 (discovered on GIST1), known also as TMEM16A and ANO1, a transmembrane protein, has been found specifically in GISTs and has emerged as a promising biomarker for GISTs (112,113). Recent studies have shown that antibodies Inhibitors,research,lifescience,medical sellckchem against DOG1 have even higher sensitivity and specificity than KIT (CD117) and CD34 with 75% to 100% overall sensitivity (113-116). DOG1 is highly expressed in KIT mutant GISTs and also can detect up to one-third of KIT-negative GISTs, which mostly have PDGFRA mutation (113,116). In addition Brefeldin_A to GISTs, DOG1 is also positive in normal gastric epithelium, some carcinomas, germ cell tumors, melanomas, and some mesenchymal tumors (113,114), such as recently reported chondroblastoma (117). Like KIT, DOG1 is also expressed in interstitial cells of Cajal serving as an internal positive control. However, DOG1 does not stain mast cells which are usually positive for KIT (112,114). Non-gastric gists and gists in specific populations Non-gastric GISTs may vary in clinical presentation, histopathology, molecular profile, prognostic significance and management strategy compared with gastric GISTs.